• Kyverna reported longer-term Phase 2 results for miv-cel in generalized myasthenia gravis during an oral presentation at American Academy of Neurology Annual Meeting.
• Follow-up showed rapid, durable symptom improvement across key clinical assessments, with responses sustained for up to one year in patients with available data.
• Patients were able to stop chronic immunosuppressive therapies through 24 weeks, supporting Kyverna’s strategy to position miv-cel as a single-dose, drug-free remission approach.
• Safety profile remained supportive of outpatient use, with no severe cytokine release syndrome or neurotoxicity events reported.
• Kyverna is enrolling Phase 3 portion of KYSA-6, with trial design also slated for presentation at AAN on April 21, 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kyverna Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-162755), on April 20, 2026, and is solely responsible for the information contained therein.